Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Next-Generation Monoclonal Antibody Blocks Malaria in Early Trial

Next-Generation Monoclonal Antibody Blocks Malaria in Early Trial News & Analysis Biotech Innovations Next-Generation Monoclonal Antibody through mosquito saliva. This effectively izing titers the most. Although the approach Blocks Malaria in Early Trial halts the infection by keeping the sporozo- also increased vaccine-related adverse An investigational monoclonal antibody ites from attaching to liver cells, preventing events, none were serious. calledL9LSprotectedmostrecipientsagainst production of the merozoites that then in- The study enrolled 1314 individuals in malaria after controlled infection in a small fectandmassivelymultiplyinredbloodcells. Argentina divided into 3 groups to receive phase 1 clinical trial, according to a report in L9LS also promotes the cytolytic destruc- their first vaccine dose: 669 received the New England Journal of Medicine. tion of sporozoites. Sputnik V C1 (Gamaleya Institute), a non- Currently, no antimalarial antibody is “Thecurrenttrialprovidesaproofofprin- replicating adenovirus vaccine; 448 approved for clinical use. If successfully ciple that prevention of malaria can be received ChAdOx1-S (Oxford-AstraZeneca), developed, adding antibodies to chemo- achieved with a next-generation monoclo- also an adenovirus vaccine; and 197 prevention and vaccine therapies might nal antibody, L9LS,” the authors wrote. The received BBIBP-CorV (Sinopharm), an inac- substantially reduce malaria-related illness authors reported that 2 phase 2 clinical trials tivated virus vaccine. The 3 first-dose and deaths. The subcutaneous injection, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Next-Generation Monoclonal Antibody Blocks Malaria in Early Trial

JAMA , Volume 328 (10) – Sep 13, 2022

Loading next page...
 
/lp/american-medical-association/next-generation-monoclonal-antibody-blocks-malaria-in-early-trial-Emiwh3Qq8r

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2022 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2022.14710
Publisher site
See Article on Publisher Site

Abstract

News & Analysis Biotech Innovations Next-Generation Monoclonal Antibody through mosquito saliva. This effectively izing titers the most. Although the approach Blocks Malaria in Early Trial halts the infection by keeping the sporozo- also increased vaccine-related adverse An investigational monoclonal antibody ites from attaching to liver cells, preventing events, none were serious. calledL9LSprotectedmostrecipientsagainst production of the merozoites that then in- The study enrolled 1314 individuals in malaria after controlled infection in a small fectandmassivelymultiplyinredbloodcells. Argentina divided into 3 groups to receive phase 1 clinical trial, according to a report in L9LS also promotes the cytolytic destruc- their first vaccine dose: 669 received the New England Journal of Medicine. tion of sporozoites. Sputnik V C1 (Gamaleya Institute), a non- Currently, no antimalarial antibody is “Thecurrenttrialprovidesaproofofprin- replicating adenovirus vaccine; 448 approved for clinical use. If successfully ciple that prevention of malaria can be received ChAdOx1-S (Oxford-AstraZeneca), developed, adding antibodies to chemo- achieved with a next-generation monoclo- also an adenovirus vaccine; and 197 prevention and vaccine therapies might nal antibody, L9LS,” the authors wrote. The received BBIBP-CorV (Sinopharm), an inac- substantially reduce malaria-related illness authors reported that 2 phase 2 clinical trials tivated virus vaccine. The 3 first-dose and deaths. The subcutaneous injection,

Journal

JAMAAmerican Medical Association

Published: Sep 13, 2022

There are no references for this article.